Company profile
MANNKIND CORP
NASDAQ:MNKDBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Furosemide | approved | — | 5 | approved |
| INSULIN HUMAN | approved | — | 5 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (52)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00511732 | phase2 | completed | 2004-06-01 | 2005-08-01 | Mannkind Corporation | 18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes |
| NCT00539396 | phase2 | completed | 2005-03-01 | — | Mannkind Corporation | A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine |
| NCT00475371 | phase1 | completed | 2007-04-01 | 2007-06-01 | Mannkind Corporation | A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males |
| NCT00570687 | phase2 | completed | 2007-09-01 | 2009-01-01 | Mannkind Corporation | A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes |
| NCT00662857 | phase2 | completed | 2008-04-01 | 2008-11-01 | Mannkind Corporation | A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 022472 | BLA | Mannkind Corporation | ||||
Loading… | ||||||
| NDA 209988 | NDA | SCPHARMACEUTICALS INC A WHOLLY OWNED SUB OF MANNKIND CORP | ||||
Loading… | ||||||